NCT02828124View on ClinicalTrials.gov

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

January 8, 2018

Study Completion Date

January 8, 2018

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

BMS-986183

specified dose on specified days

BIOLOGICAL

Nivolumab

specified dose on specified days

Trial Locations (4)

10048

Local Institution, Taipei

169610

Local Institution, Singapore

K1H 8L6

Local Institution, Ottawa

05505

Local Institution, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02828124 - A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Biotech Hunter | Biotech Hunter